var data={"title":"Nizatidine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nizatidine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6665?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nizatidine-drug-information\" class=\"drug drug_general\">see &quot;Nizatidine: Drug information&quot;</a> and <a href=\"topic.htm?path=nizatidine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nizatidine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202316\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Axid AR [OTC] [DSC];</li>\n      <li>Axid [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202317\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Nizatidine;</li>\n      <li>Axid;</li>\n      <li>Gen-Nizatidine;</li>\n      <li>Novo-Nizatidine;</li>\n      <li>Nu-Nizatidine;</li>\n      <li>PMS-Nizatidine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060591\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Histamine H<sub>2</sub> Antagonist</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060584\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=nizatidine-drug-information\" class=\"drug drug_general\">see &quot;Nizatidine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>GERD, treatment: </b>Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &le;11 years: Limited data available: 5 mg/kg/dose twice daily; maximum daily dose: 300 mg/<b>day </b>(AAP [Lightdale] 2013; Vandenplas 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 150 mg twice daily; maximum daily dose: 300 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Esophagitis, treatment</b>: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;6 months and Children &le;11 years: Limited data available: 5 mg/kg/dose twice daily. Dosing based on a double blind, placebo controlled trial in 26 pediatric patients (treatment group: n=13; age range: 0.5 to 12 years) with mild to moderate esophagitis (Simeone 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 150 mg twice daily; maximum daily dose: 300 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Duodenal ulcer:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i> 300 mg once daily at bedtime or 150 mg twice daily for up to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Maintenance of healing:</i> 150 mg once daily at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastric ulcer, benign:</b> Oral: 150 mg twice daily or 300 mg once daily at bedtime for up to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>GERD:</b> Oral: 150 mg twice daily for up to 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Helicobacter pylori</i></b> <b>eradication:</b> Oral: 150 mg twice daily (in combination with amoxicillin and clarithromycin [or bismuth, metronidazole, and tetracycline]) for 10 to 14 days (ACG [Chey 2007]; Graham 2003; Talley 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Active treatment: Children &ge;12 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 20 to 50 mL/minute: 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;20 mL/minute: 150 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance treatment: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 20 to 50 mL/minute: 150 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;20 mL/minute: 150 mg every 3 days</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202292\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Axid: 300 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg, 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg/mL (473 mL [DSC], 480 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Axid AR: 75 mg [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202278\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060594\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May administer with or without food; do not administer or mix capsule contents with apple juice</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25234198\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nizatidine is stable for 48 hours at room temperature when the contents of a capsule are mixed in Gatorade&reg; lemon-lime, Cran-Grape&reg; grape-cranberry drink, V8&reg;, or aluminum- and magnesium hydroxide suspension (approximate concentration 2.5 mg/mL) (Lantz 1990)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060593\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Treatment of endoscopically diagnosed esophagitis (erosive and ulcerative) and associated heartburn due to gastroesophageal reflux disease (GERD) (FDA approved in ages &ge;12 years and adults); treatment and maintenance therapy of duodenal ulcer (FDA approved in adults); treatment of active benign gastric ulcer (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule: Treatment and maintenance therapy of duodenal ulcer; treatment of active benign gastric ulcer; treatment of endoscopically diagnosed esophagitis (erosive and ulcerative) and associated heartburn due to gastroesophageal reflux disease (GERD) (All indications: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202366\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Axid may be confused with Ansaid</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tazac [Australia] may be confused with Tazact brand name for piperacillin/tazobactam [India]; Tiazac brand name for dilTIAZem [US, Canada]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202364\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, dizziness, drowsiness, headache, insomnia, irritability (children), nervousness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, flatulence, heartburn, nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough (children), nasal congestion (children), nasopharyngitis (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, anemia, bronchospasm, confusion, eosinophilia, exfoliative dermatitis, gynecomastia, hepatitis, immune thrombocytopenia, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, jaundice, laryngeal edema, serum sickness-like reaction, thrombocytopenia, vasculitis, ventricular tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202297\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to nizatidine, other H<sub>2</sub> antagonists, or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202282\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vitamin B<sub>12</sub> deficiency: Prolonged treatment (&ge;2 years) may lead to vitamin B<sub>12</sub> malabsorption and subsequent vitamin B<sub>12</sub> deficiency. The magnitude of the deficiency is dose-related and the association is stronger in females and those younger in age (&lt;30 years); prevalence is decreased after discontinuation of therapy (Lam 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with moderate to severe renal impairment; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Use of gastric acid inhibitors, including proton pump inhibitors and H<sub>2</sub> blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients (Canani 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202352\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202287\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12649&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Acalabrutinib.  Management: To minimize the potential for a significant interaction, separate administration of these agents by giving acalabrutinib 2 hours before ingestion of a histamine-2 receptor antagonist.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefditoren: Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpodoxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefuroxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Histamine H2 Receptor Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with H2-antagonists should be avoided in patients who are being treated with delavirdine.  The clinical significance of short-term H2-antagonist therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Histamine H2 Receptor Antagonists may increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or after administration of a histamine H2-antagonist, and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Histamine H2 Receptor Antagonists may decrease the absorption of Iron Salts. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of Itraconazole.  Management: When this combination is used, the itraconazole should be administered with a non-diet cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Histamine H2 Receptor Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Ledipasvir. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesalamine: Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Histamine H2 Receptor Antagonists may increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Histamine H2 Receptor Antagonists may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be impaired by H2-antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Neratinib. Specifically, histamine H2 receptor antagonists may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nilotinib.  Management: The nilotinib dose should be given 10 hours after or 2 hours before the H2 receptor antagonist in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: Histamine H2 Receptor Antagonists may decrease the serum concentration of PAZOPanib.  Management: Avoid the use of histamine H2-antagonists in combination with pazopanib.  Strategies to minimize the expected interaction between these agents (eg, dose separation) have not been investigated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of Posaconazole.  Management: Avoid concurrent use of oral suspension with H2-antagonists whenever possible. Monitor patients closely for decreased antifungal effects if this combination is used. Delayed-release posaconazole tablets may be less likely to interact.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Risedronate: Histamine H2 Receptor Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Histamine H2 Receptor Antagonists may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Histamine H2 Receptor Antagonists may diminish the diagnostic effect of Secretin. Specifically, use of H2-Antagonists may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of histamine H2-antagonists (H2RAs) and secretin. Discontinue H2RAs at least 2 days prior to secretin administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: Histamine H2 Receptor Antagonists may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Velpatasvir. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202312\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Prolonged treatment (&ge;2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202289\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202301\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Nizatidine crosses the placenta (Dicke 1988). Information related to the use of nizatidine in pregnancy is limited; other agents may be preferred (Richter 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202281\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitive inhibition of histamine at H<sub>2</sub>-receptors of the gastric parietal cells, which inhibits gastric acid secretion, gastric volume, and hydrogen ion concentration are reduced. Does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion, or serum gastrin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202296\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.8 to 1.5 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 35% to alpha-1 acid glycoprotein </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Partially hepatic; forms metabolites </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: &gt;70% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 1 to 2 hours; prolonged with moderate to severe renal impairment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: 0.5 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&gt;90%; ~60% as unchanged drug); feces (&lt;6%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11430199\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 2.5 mg/mL oral solution may be made with capsules and one of three different vehicles (lemon-lime Gatorade&reg;, Ocean Spray&reg; Cran-Grape&reg; juice or V8&reg; 100% vegetable juice). Empty the contents of one 300 mg capsule in a mortar. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &quot;shake well&quot;. Stable for 2 days refrigerated.</p>\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202300\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Nizatidine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $143.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $140.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nizatidine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg/mL (480 mL): $524.49</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202303\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acinon (JP);</li>\n      <li>Acitidin (KR);</li>\n      <li>Acitidine (KR);</li>\n      <li>Axadine (KR);</li>\n      <li>Axid (AE, BH, CN, CY, CZ, HR, HU, JO, LB, MX, QA, SA, VN);</li>\n      <li>Axid Pulvules (BF, BG, BJ, CI, ET, GB, GH, GM, GN, GR, ID, IE, KE, KR, LR, MA, ML, MR, MU, MW, MY, NE, NG, PK, PL, SC, SD, SE, SG, SL, SN, TN, TR, TZ, UG, VE, ZA, ZM, ZW);</li>\n      <li>Calmaxid (CH);</li>\n      <li>Cronizat (IT);</li>\n      <li>Fixit (AE, KW, QA, SA);</li>\n      <li>Gastrax (DE);</li>\n      <li>Jadin (KR);</li>\n      <li>Nacid (KR);</li>\n      <li>Naxidin (HN, HU);</li>\n      <li>Naxidine (NL);</li>\n      <li>Nizac (AU);</li>\n      <li>Nizaractine (KR);</li>\n      <li>Nizatid (BD, KR);</li>\n      <li>Nizax (DE, DK, FI, IT, NO);</li>\n      <li>Nizaxid (CL, FR, LU, PT);</li>\n      <li>Nolcer (PH);</li>\n      <li>Panaxid (BE, LU);</li>\n      <li>Tazac (AU, TW);</li>\n      <li>Tinza (KR);</li>\n      <li>Ulxit (AT);</li>\n      <li>Zastidin (VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Canani RB, Cirillo P, Roggero P, et al, &quot;Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,&quot; <i>Pediatrics</i>, 2006, 117(5):e817-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/16651285/pubmed\" target=\"_blank\" id=\"16651285\">16651285</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection,&rdquo; <i>Am J Gastroenterol</i>, 2007 102(8):1808-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/17608775/pubmed\" target=\"_blank\" id=\"17608775\">17608775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dicke JM, Johnson RF, Henderson GI, et al. A comparative evaluation of the transport of H<sub>2</sub>-receptor antagonists by the human and baboon placenta. <i>Am J Med Sci</i>. 1988 Mar;295(3):198-206.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/2895583/pubmed\" target=\"_blank\" id=\"2895583\">2895583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12755836\"></a>Graham DY, Hammoud F, El-Zimaity HM, Kim JG, Osato MS, El-Serag HB. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. <i>Aliment Pharmacol Ther</i>, 2003;17(10):1229-1236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/12755836/pubmed\" target=\"_blank\" id=\"12755836\">12755836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/24327038/pubmed\" target=\"_blank\" id=\"24327038\">24327038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lantz MD, Wozniak TJ. Stability of nizatidine in extemporaneous oral liquid preparations. <i>Am J Hosp Pharm</i>. 1990;47(12):2716-2719.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/1980576/pubmed\" target=\"_blank\" id=\"1980576\">1980576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lightdale JR, Gremse DA; Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: management guidance for the pediatrician. <i>Pediatrics</i>. 2013;131(5):e1684-1695.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/23629618/pubmed\" target=\"_blank\" id=\"23629618\">23629618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mikawa K, Nishina K, Maekawa N, et al, &ldquo;Effects of Oral Nizatidine on Preoperative Gastric Fluid pH and Volume in Children,&rdquo; <i>Br J Anaesth</i>, 1994, 73(5):600-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/7826786/pubmed\" target=\"_blank\" id=\"7826786\">7826786</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nizatidine capsule [prescribing information]. Princeton, NJ: Sandoz, Inc; October 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nizatidine solution [prescribing information]. Bridgewater, NJ: Gemini Laboratories, LLC; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orenstein SR, Gremse DA, Pantaleon CD, Kling DF, Rotenberg KS. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. <i>Clin Ther</i>. 2005;27(4):472-483.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/15922820/pubmed\" target=\"_blank\" id=\"15922820\">15922820</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richter JE. Review article: the management of heartburn in pregnancy. <i>Aliment Pharmacol Ther</i>. 2005;22(9):749-757. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/16225482/pubmed\" target=\"_blank\" id=\"16225482\">16225482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simeone D, Caria MC, Miele E, et al, &ldquo;Treatment of Childhood Peptic Esophagitis: A Double-Blind Placebo-Controlled Trial of Nizatidine,&rdquo; <i>J Pediatr Gastroenterol Nur</i>, 1997, 25(1):51-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/9226527/pubmed\" target=\"_blank\" id=\"9226527\">9226527</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9678811\"></a>Talley NJ, Chang FY, Wyatt JM, et al. Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. <i>Aliment Pharmacol Ther</i>. 1998;12(6):527-532.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/9678811/pubmed\" target=\"_blank\" id=\"9678811\">9678811</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19745761\"></a>Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). <i>J Pediatr Gastroenterol Nutr</i>. 2009;49(4):498-547.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nizatidine-pediatric-drug-information/abstract-text/19745761/pubmed\" target=\"_blank\" id=\"19745761\">19745761</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12649 Version 141.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F202316\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F202317\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060591\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060584\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F202292\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F202278\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060594\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F25234198\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060593\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F202366\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F202364\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F202297\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F202282\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F202352\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F202287\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F202312\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F202289\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F202301\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F202281\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F202296\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F11430199\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F202300\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F202303\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12649|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nizatidine-drug-information\" class=\"drug drug_general\">Nizatidine: Drug information</a></li><li><a href=\"topic.htm?path=nizatidine-patient-drug-information\" class=\"drug drug_patient\">Nizatidine: Patient drug information</a></li></ul></div></div>","javascript":null}